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Abstract
Background: HIV-associated sensory neuropathy (HIV-SN) is one of the most common forms of peripheral
neuropathy, affecting about 30% of people with acquired immune deficiency syndrome (AIDS). The symptoms of
HIV-SN are dominated by neuropathic pain. Glia activation in the spinal cord has become an attractive target for
attenuating chronic pain. This study will investigate the role of spinal TNFa released from glia in HIV-related
neuropathic pain.
Results: Peripheral gp120 application into the rat sciatic nerve induced mechanical allodynia for more than 7
weeks, and upregulated the expression of spinal TNFa in the mRNA and the protein levels at 2 weeks after gp120
application. Spinal TNFa was colocalized with GFAP (a marker of astrocytes) and Iba1 (a marker of microglia) in
immunostaining, suggesting that glia produce TNFa in the spinal cord in this model. Peripheral gp120 application
also increased TNFa in the L4/5 DRG. Furthermore, intrathecal administration of TNFa siRNA or soluble TNF
receptor reduced gp120 application-induced mechanical allodynia.
Conclusions: Our results indicate that TNFa in the spinal cord and the DRG are involved in neuropathic pain,
following the peripheral HIV gp120 application, and that blockade of the glial product TNFa reverses neuropathic
pain induced by HIV gp120 application.
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Background
Infection of the central nervous system with the human
immunodeficiency virus type 1 (HIV-1) can lead to cog-
nitive, motor and sensory disorders. HIV-associated sen-
sory neuropathy (HIV-SN) is one of the most common
forms of peripheral neuropathy, affecting about 30% of
people with acquired immune deficiency syndrome
(AIDS) [1,2]. The symptoms of HIV-SN are dominated
by neuropathic pain [3,4]. The mechanisms underlying
HIV-SN remain unclear. Astrocytosis and subsequent
neuron death are two hallmarks of HIV infection in the
central nervous system [5]. Direct infection of neurons
by HIV is thought to be unlikely [6,7]; HIV-1 binds via
the external envelope proteins (e.g., gp120) to the che-
mokine receptors CXCR4 and/or CCR5 (co-receptors of
gp120) on the cells. Previous reports have suggested
that gp120 application contributes to neurotoxicity in in
vitro and nociceptive behaviour in rodents [8-11].
Indeed, it has been demonstrated that gp120 application
is capable of producing pain when administered periph-
erally [12] or centrally [13]. Proposed mechanisms
underlying gp120 application induced a chronic noci-
ceptive effect included spinal gliosis [8]. HIV gp120
application might produce such effects indirectly, via an
action on glial cells, causing them to release inflamma-
tory cytokines [13].
Dysregulation of cytokines has been implicated in a
variety of painful neurological diseases and in animal
models of neuropathic pain. HIV-1 transgenic rats
overexpressing gp120 induce reactive gliosis (in the
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brain), a marker for central nervous system damage
[14]. HIV virus infection is able to increase the pro-
duction and utilization of several cytokines, such as
TNFa and IL-1b [15]. Cerebrospinal fluid from most
of the patients with AIDS has increased levels of
TNFa [16]. A transgenic rat developed using an HIV-1
construct, with deleted gag and pol genes, shows a
strikingly high expression of TNFa [17]. A mouse
model of systemic HIV-1 infection increases expression
of IL-1b [18]. The viral gp120 induces the release of
TNFa and IL-1b whose interaction have synergistic
activities [19]; TNFa and IL-1b upregulate HIV-1
expression in cells infected by HIV [20]. This may
result in an HIV gp120-cytokines reciprocal amplifica-
tion with potential deleterious effects (a positive feed-
back cycles) [19]. An elevated baseline of TNFa level
among HIV-1 positive individuals, may lead to addi-
tional neurodegeneration [21]. However, the role of
spinal cytokines in the neuropathic pain induced by
gp120 is not clear. In the present study, we investi-
gated the role of TNFa in the neuropathic pain
induced by gp120 application into the sciatic nerve.
Results
Peripheral gp120 application induced mechanical
allodynia
Before peripheral gp120 application (50 or 400 ng of
gp120 in 250 μl of 0.1% RSA) into the sciatic nerve, the
baseline of mechanical threshold was around 11 grams.
After the gp120 application, mechanical threshold
decreased significantly on the ipsilateral paw from day 5;
mechanical threshold reached the lowest values at 2 weeks
after gp120 application. In the sham group treated with
RSA, rats showed no significant changes in mechanical
threshold throughout the 7-week testing period. The dif-
ference in the threshold was very significant between the
sham and gp120 application (50 ng), F(1,13) = 6.899, p <
0.02 vs sham, n = 7-8; high concentration of gp120
(400 ng) furthermore lowered the threshold, F(1,14) =
22.672, p < 0.001 vs sham, n = 7-9 (Figure 1). There is a
significant difference between two doses of gp120, F(1,15) =
5.479, p < 0.05, n = 8, General linear model, repeated mea-
sured, SPSS (Figure 1).
Peripheral gp120 application upregulated the expression
of TNFa mRNA in the spinal cord
Original studies show that a gp120 application into the
sciatic nerve induced overexpression of TNFa in the
sciatic nerve [8]. In the current study, two weeks after
gp120 application, the lumbar spinal dorsal horn was
harvested and mRNA expression of TNFa was tested
using quantitative real time RT-PCR. Application of
gp120 into the nerve significantly induced the upregula-
tion of mRNA of TNFa (Figure 2).
Peripheral gp120 application upregulated the expression
of GFAP, Iba1 and TNFa
Previous studies show that a gp120 application into the
sciatic nerve induced overexpression of spinal GFAP (a
marker of astrocytes) and OX-42 (a marker of microglia)
immunoreactivity, using immunoreactive density at the
spinal dorsal horn at 5, 22 and 30 days after gp120 applica-
tion [8,22]. In our behavioral study (Figure 1), we observed
that allodynia reached the lowest value at 2 weeks, so in
the current study we focused on a 2-week timepoint to
investigate the neurochemical changes. We found that the
gp120 application significantly increased expression of
GFAP, Iba1 (a marker of microglia), and TNFa protein in
Figure 1 The time course of the mechanical threshold in the
model of peripheral gp120 application. Rats exposed to
perineural HIV-1 gp120 application (50 ng) developed a persistent,
mechanical allodynia of the ipsilateral hind paw compared to the
sham group, F(1,13) = 6.899, p < 0.021 vs sham, n = 7-8; HIV-1 gp120
application (400 ng) further induced mechanical allodynia of the
ipsilateral hind paw, F(1,14) = 22.672, p < 0.001 vs sham, n = 7-9,
General linear model, repeated measured, SPSS.
Figure 2 The expression of spinal TNFa mRNA in the
perineural gp120 application model using quantitative real
time RT-PCR. Two weeks after gp120 application, left L4/5 spinal
dorsal horns were harvested under anesthesia and mRNA
expression was examined using quantitative real time RT-PCR.
Perineural gp120 application significantly upregulated spinal mRNA
of TNFa. * p < 0.05 vs sham, n = 3-5, t test.
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the spinal dorsal horn, compared to the sham group using
Western blots (Figure 3). To our knowledge, we were the
first to observe that the gp120 application increased
expression of TNFa in the spinal dorsal horn.
Examination of expression of TNFa in the spinal dorsal
horn using immunohistochemistry in gp120 application-
induced neuropathy
Spinal gliosis occurs following perineural HIV-gp120 appli-
cation [8,11]. A substantial increase in TNFa immunoreac-
tive staining was observed in the ipsilateral L5 spinal cord.
The most prominent increase was found in the medial
laminas I-IV of the dorsal horn, but the deep dorsal horn
(laminas V and VI) and the ventral horn also showed an
increase in TNFa immunostaining (Figure 4). However,
less immunostaining of spinal TNFa was seen in the con-
tralateral side of the gp120 application. Triple-label immu-
nostaining of GFAP, TNFa and NeuN was carried out.
There was an almost complete colocalization between
GFAP (blue) and TNFa (red) imaging, but TNFa did not
colocalize with NeuN (green), which suggested that TNFa
was located in astrocytes, but not neurons (Figure 5). Dou-
ble-label immunostaining of Iba1 and TNFa in the spinal
dorsal horn was carried out in rats treated with gp120
application for 2 weeks (Figure 6). There was marked colo-
calization between Iba1 and TNFa imaging, suggesting
that TNFa may also be released from microglia.
Peripheral gp120 application increased the expression of
TNFa in the DRG
Sensory DRG neurons play an important role in the reg-
ulation of nociceptive input transduction.
Previous studies show that nerve injury induces upre-
gulation of TNFa in the DRG neurons [23,24]. In the
study with cultured DRG cells, CXCR4 binding on
Schwann cells by gp120 application results in the release
of RANTES, which induces TNFa production by DRG
neurons, and subsequent TNFR1-mediated neurotoxicity
in an autocrine/paracrine fashion [9]. In the current
Figure 3 The expression of spinal GFAP, Iba1, and TNFa in the gp120 application model. Two weeks after gp120 application, the left L4/5
spinal dorsal horns were harvested under anesthesia, and protein expression of spinal GFAP, Iba1, and TNFa was tested using Western blots.
Perineural gp120 application significantly induced the upregulation of GFAP, Iba1, and TNFa in the spinal cord level. *p < 0.05 vs sham, ** p <
0.01 vs sham, t test, n = 3-4.
Figure 4 Immunohistochemistry shows TNFa immunostaining
in the whole spinal cord in rats with application of gp120 into
the sciatic nerve. Fourteen days after gp120 application, a
substantial increase in the intensity of TNFa immunostaining was
observed in the ipsilateral L4/5 spinal cord. The most prominent
increase was found in the medial laminas I-IV of the dorsal horn,
but the deep dorsal horn (laminas V and VI) and the ventral horn
also showed an increase in TNFa immunostaining.
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study, we observed a clear TNFa immunostaining in the
DRG in rats with gp120 application (Figure 7B) com-
pared to the sham group (Figure 7A). We found that
TNFa was significantly increased in the gp120 applica-
tion compared to the sham group using Western blots
(Figure 7C).
The antinociceptive effect of glial inhibitor on the gp120
application-induced mechanical allodynia
Furthermore, we investigated the antinociceptive effect
of glial inhibitor on the gp120 application-induced
mechanical allodynia. Intrathecal administration of pen-
toxifylline, a non-specific glial cytokine inhibitor [25,26]
significantly reversed the mechanical allodynia in the
model (Figure 8), F(1,8) = 13.650, p = 0.006, n = 5,
General Linear Model, repeated measure, SPSS, which
was consistent with that reported in other neuropathic
pain models [25,27].
The antinociceptive effect of soluble TNF receptor on the
gp120 application-induced mechanical allodynia
The results above suggest that spinal TNFa plays a role
in the gp120 application-induced sensory neuropathy.
Furthermore, we investigated the antinociceptive effect
of soluble TNF receptor on the gp120 application-
induced mechanical allodynia. Soluble TNF receptor
may block TNFa from binding to a membrane TNF
receptor on the cell surface, to neutralize the biological
effect of TNFa. Overexpression of soluble TNF receptor
by HSV vectors reversed the increase in TNFa and
mechanical allodynia in the neuropathic pain models
[28,29]. At 2 weeks after gp120 application, intrathecal
recombinant soluble TNF receptor or vehicle was admi-
nistered 3 times at 12 hour intervals. Mechanical thresh-
old was tested after the last injection. Mechanical
threshold increased significantly at 30 and 60 min in
rats with soluble TNF receptor, but not the vehicle
(Figure 9A), F(1, 11) = 10.808, p = 0.007, n = 6-7, General
linear model, repeated measure, SPSS.
TNFa siRNA knockdown in vitro and in vivo
We examined whether TNFa siRNA knockdown
reversed the neuropathic pain induced by gp120 applica-
tion. We used cultured glial cells to identify the efficacy
of TNFa siRNA that we ordered. We have found that
the LPS effectively stimulates HAPI cells (one of glial
cell lines) to release TNFa [30]. HAPI cells were pre-
treated with TNFa siRNA or mismatch RNA for 24
hours, and then stimulated with LPS for 6 hours. The
supernatant was collected for testing the expression of
TNFa with an ELISA kit (R&D). Pretreatment with
TNFa siRNA, but not mismatch RNA suppressed the
Figure 5 Immunofluorescent photomicrographs of TNFa in the
spinal dorsal horn in rats treated with gp120. Triple-label
immunostaining of GFAP, TNFa and NeuN was carried out. There
was an almost complete colocalization between GFAP (blue) and
TNFa (red) imaging, but TNFa did not colocalize with NeuN (green),
which suggests that TNFa is located in the astrocytes, but not
neurons. Arrow shows the colocalization.
Figure 6 Colocalization of TNFa and Iba1 in the spinal cord. Double-label immunostaining of Iba1 and TNFa in the spinal dorsal horn was
carried out in rats treated with gp120 application for 2 weeks. There was marked colocalization between Iba1 and TNFa imaging. Scale bar,
50 μm.
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expression of TNFa in the cultured medium (Figure
9B). In the control group without LPS, non TNFa was
detected (data not shown). Intrathecal siRNA of TNFa
or mismatch RNA (10 μg) was given 2 times at 12-hour
intervals. Mechanical threshold was tested after the last
injection, and increased significantly at 6 and 24 hours
in rats with TNFa siRNA, but not the mismatch RNA
(Figure 9C), F(1,12) = 20.293, p = 0.001, n = 7, General
Linear Model, repeated measure with SPSS.
Figure 7 Peripheral gp120 application increased the expression of TNFa in the DRG. At 2 weeks after gp120 application, a clear
immunostaining of TNFa in the DRG was shown (B), but TNFa in the sham group was weak (A). Bar graph showed TNFa expression in the
DRG using Western blots (C), p < 0.05 vs sham, n = 3, t test.
Figure 8 The antinociceptive effects of glial inhibitor in rats
treated with gp120 application. At 2 weeks after gp120
application, intrathecal administration of pentoxifylline significantly
reversed the allodynia in the model, F(1, 8) = 13.650, p = 0.006, n =
5, General linear model, repeated measure, SPSS (Figure 8).
Figure 9 The antinociceptive effects of recombinant soluble
TNF receptor or TNFa knockdown with TNFa siRNA in rats
treated with gp120 application. (A) Rats received an intrathecal
injection of recombinant soluble TNF receptor I or vehicle.
Administration of recombinant soluble TNF receptor I, but not
vehicle, reversed the mechanical threshold, F(1, 11) = 10.808, p =
0.007, n = 6-7, General linear model, repeated measure, SPSS. (B)
The downregulation of TNFa in the cultured glial cell line by TNFa
siRNA. The glial cells were pretreated with the TNFa siRNA or the
mismatch RNA, and then stimulated with LPS. TNFa siRNA
significantly lowered the TNFa expression in the cells treated with
LPS, *p < 0.01, t test, n = 3. (C) The effect of intrathecal TNFa siRNA
on the mechanical threshold in rats treated with gp120 application.
Administration of TNFa siRNA, but not the mismatch RNA, reversed
the mechanical threshold, F(1, 12) = 20.293, p = 0.001, n = 7, General
linear model, repeated measure, SPSS.
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Discussion
Previous studies indicate that TNFa is involved in the
development of chronic pain. There is growing evidence
suggesting that glial activation plays an important role
in the HIV-sensory neuropathy. The current study
showed 1) that HIV gp120 application into the sciatic
nerve induced neuropathic pain behavior, and upregu-
lated the expression of spinal GFAP, Iba1, and TNFa; 2)
that TNFa was colocalized with either GFAP or Iba1 in
the spinal cord, suggesting that TNFa is released from
the activated astrocytes or microglia; 3) that gp120
application also induced upregulation of TNFa in the
DRG; and 4) that knockdown of TNFa with siRNA or
recombinant soluble TNF receptor reversed mechanical
allodynia induced by gp120 application.
Neuropathic pain is disorder resulting from damage or
alteration to nerve structures in the absence of demon-
strated tissue damage. HIV infection might influence the
basic neurobiology, neurological morphology, and clinical
management of neurological dysfunction [31-33]. The
entry of HIV into cells requires the sequential interaction
of the viral exterior envelope glycoprotein, gp120 (cleavage
of gp160), with the CD4 glycoprotein and chemokine
receptors on the cell surface [34-37], facilitating receptor
signaling in both the peripheral nervous system and the
CNS [36,38,39]. In in vitro studies, HIV-gp120 binding to
Schwann cells through CXCR4 results in the release of
RANTES, which induces TNFa production by DRG, and
subsequent TNFR1-mediated neurotoxicity in an auto-
crine/paracrine fashion [9]. In in vivo studies, HIV-1 trans-
genic rats overexpressing gp120 induce reactive gliosis in
brain [14]. Astrocyte activation or astrocytosis may directly
contribute to HIV-associated neurological disorders [40].
Injection of gp120 into the hindpaws produces pain hyper-
sensitivity by directly exciting primary nociceptive neurons
[41]. Intrathecal injection of gp120 recombinant protein
induces an acute painful behavior and proinflammatory
cytokine release in the spinal cord [10]. Cerebrospinal
fluid from most patients with AIDS shows an increase in
TNFa [16]. The HIV gp120 induces the release of IL-1b
and TNFa whose interaction has synergistic activities [19].
In clinic, TNFa has also been implicated in the pathogen-
esis of HIV-1 infection, promoting HIV replication in T
cell lines and in lymphocytes in HIV-infected patients
[42]. Serum concentrations of TNFa have been shown to
increase as HIV-1 infection progresses [43], suggesting
that TNFa may contribute to disease progression. Thus,
inhibition of TNFa in the setting of HIV infection has
been appealing, at least in theory. However, whether
TNFa is involved in the development of neuropathic pain
in the HIV/AIDS patients is not clear.
Inflammation of peripheral nerves causes sustained
increased electrical activity in the C/Aδ fibers, that leads
to transcriptional and post-translational changes in sec-
ond order neurons in the spinal dorsal horn, that are
characteristic of chronic pain [44]. Evidence indicates
that peripheral nerve damage or inflammation, results in
the activation of glia in the dorsal horn that plays an
important role in the pathogenesis of neuropathic pain
[45-47]. After peripheral nerve injury or spinal cord
injury TNFa in spinal microglia or astrocytes is
increased [28,29,46]. In the current study, we used the
peripheral gp120 application model and also found simi-
lar results.
In the chronic constriction injury model of peripheral
neuropathic pain, neutralizing antibodies to TNF and to
TNFR1 reduce thermal hyperalgesia and mechanical allo-
dynia [48], and intrathecal administration of the recombi-
nant soluble TNFR (sTNFR) peptide (etanercept), prior
to selective spinal nerve ligation reduces mechanical allo-
dynia [40]. Administration of drugs that block the effects
of these cytokines [24,49] or that block glial activation
[50] can be used to prevent or reverse neuropathic pain,
which is consistent with our results. Previous studies
have shown that overexpression of spinal TNFa released
from microglia and/or astrocytes play an important role
in the different neuropathic pain models [28,29,51,52].
Our current study showed that TNFa in the DRG might
also involve neuropathic pain in this model, which is con-
sistent with previous reports [23,24].
Transmembrane TNFa, a precursor of the soluble
form of TNFa (sTNFa), is expressed on activated
macrophages and lymphocytes as well as other cell types
(e.g. glia in the CNS). After processed by TNF-alpha-
converting enzyme, the soluble form of TNFa is cleaved
from transmembrane TNFa and mediates its biological
activities [53]. Although many studies demonstrate
increased TNFa mRNA and/or protein in neuropathic
pain, to our knowledge, none of those reports demon-
strate the release of sTNFa in the spinal cord in models
of persistent pain. In our previous studies of neuro-
pathic pain induced by spinal cord injury [28], spinal
nerve ligation [29], and of inflammatory pain [30], we
have found by Western blot that there is an increase in
full-length mTNFa (26 kD) without detectable sTNFa
in the spinal dorsal horn. In the current study, we did
not observe sTNFa either.
In summary, there is abundant evidence to suggest
that one of the important elements is neuroimmune
activation of glia and glial products in the spinal cord in
the neuropathic pain state [54-56]. While the mechan-
isms underlying HIV-related neuropathic pain are poorly
understood, the results of the current investigation pro-
vide an important insight into the pathogenesis of
chronic pain. Other targets (e.g., IL-1b, p-p38) will be
addressed in the near future.
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Methods
Animal experiments
Male Sprague-Dawley rats weighing 225-250 g were
housed one to three per cage approximately 7 days prior
to the beginning of the study. Free access to food and
water and maintained on a 12:12, light: dark schedule at
21°C and 60% humidity. All housing conditions and
experimental procedures were approved by the Univer-
sity Animal Care and Use Committee and were con-
ducted in accordance with the ethical guidelines of the
International Association for the Study of Pain [57].
Intrathecal catheter implantation
For intrathecal administration, intrathecal catheters were
implanted under isoflurane anesthesia [58]. A polyethy-
lene (PE-10) catheter filled with 0.9% saline was
advanced 8 cm caudally through an incision in the
atlanto-occipital membrane to position its tip at the
level of the lumbar enlargement. The rostral tip of the
catheter was passed subcutaneously, externalized on top
of the skull, and sealed with a stainless-steel plug. Ani-
mals showing neurological deficits after implantation
were excluded. Animals were used within 5 days after
implantation of the catheter.
Perineural gp120 application model
Under anesthesia, male Sprague-Dawley rats (225-250
grams) were used and the left sciatic nerve was exposed in
the popliteal fossa without damaging the nerve construc-
tion. A 2 × 6 mm strip of oxidized regenerated cellulose
was previously soaked in 250 μl of a 0.1% rat serum albu-
min (RSA) in saline, containing 50 or 400 ng of gp120
(Immunodiagnostics, Bedford, MA.) or 0.1% RSA in saline
for the sham surgery. A length 3-4 mm of sciatic nerve
was wrapped loosely with the previously soaked cellulose,
proximal to the trifurcation not to cause any nerve con-
striction and left in situ [8,22]. The incision was closed
with 4/0 sutures. Application of gp120 induced a marked
decrease in the mechanical threshold.
Mechanical threshold
Animals were placed in transparent plastic cubicles on a
mesh floor for an acclimatization period of at least 30
min on the morning of the test day. Mechanical allody-
nia was determined by assessing paw withdrawal to von
Frey hairs of graded tensile strength. A series of cali-
brated von Frey filaments were presented serially to the
hind paw in ascending order of strength, with each fila-
ment applied for 6 s with sufficient force to cause slight
bending against the paw. A positive response was
defined as rapid withdrawal and/or licking of the paw
immediately upon application of the stimulus, which
was then followed by application of the next finer von
Frey filament. After a negative response, the next higher
von Frey filament was applied. Animals that did not
respond to a pressure of 15.1 g were assigned to this
cutoff value. The tactile stimulus producing a 50% likeli-
hood of withdrawal was determined using the up-down
method [59,60]
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated from the spinal cord using TRI-
zol reagent (Invitrogen, Camarillo, CA, USA), treated
with RNase-free DNase-I (Roche, Indianapolis, IN, USA)
and re-purified, and then quantified spectrophotometri-
cally. Total RNA (1 μg) was reverse transcribed (Omnis-
cript RT kit, Qiagen, Valencia, CA, USA) using random
hexamers PCR primer. cDNA prepared from mRNA
was amplified using the following primer sets: GAPDH-
forward 5’-GTTTGTGATGGGTGTGAACC-3’ and
-reverse 5’-TCTTCTGAGTGGCAGTGATG-3’; TNFa-
forward 5’-CTTCAAGGGACAAGGCTG-3’ and -reverse
5’-GAGGCTGACTTTCTCCTG-3’. PCR was performed
with equal amounts of cDNA in the GeneAmp 7700
sequence detection system (Applied Biosystems, Foster
City, CA, USA), using SYBR® Green PCR Master Mix
(Applied Biosystems, Foster City, CA, USA). Reactions
(total volume, 25 μl) were incubated at 95°C for 10 min,
followed by 40 cycles of 15 s at 95°C and 1 min at 60°C.
Each sample was measured, and data points were exam-
ined for integrity by analysis of the amplification plot.
The comparative cycle threshold (Ct) method was used
for relative quantification of gene expression. The
amount of mRNA, normalized to the endogenous con-
trol (GAPDH) and relative to a calibrator, is given by 2-
ΔΔCt, with Ct indicating the cycle number at which the
fluorescence signal of the PCR product crosses an arbi-
trary threshold set within the exponential phase of the
PCR, and ΔΔCt = [(Cttarget (unknown sample) - Ctend.control
(unknown sample))] - [(Cttarget (calibrator sample) - Ctend. control
(calibrator sample))] as previously described [61].
Western Blots
The tissues were homogenized in protein lysis buffer
(150 mM sodium chloride, 1.0% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) contain-
ing protease inhibitors and phosphatase inhibitors
(Phosphatase Inhibitor Cocktails 1/2, Sigma, St. Louis,
MO, USA). The homogenate was centrifuged at 18,000
g for 20 min at 4°C. The supernatant was collected and
assayed for protein concentration using the DC protein
assay (Bio-Rad, Hercules, CA, USA). Aliquots containing
30 μg of protein were dissolved in Laemmli buffer and
denatured at 95°C for 5 min; the proteins were sepa-
rated by 10% Tris-glycine SDS-PAGE gel and trans-
ferred to a PVDF membrane. The membranes were
blocked with 5% nonfat dry milk in PBS buffer, and
then incubated with primary antibodies for 1 h at room
temperature, including mouse anti-GFAP (1:10,000,
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Sigma, St. Louis, MO, USA), rabbit anti-Iba1 antibody
(1:1000, Wako, Richmond, VA), rabbit polyclonal anti-
TNFa (1 : 500, Chemicon, Temecula, CA) and mouse
anti-b-actin, 1 : 8000, monoclonal antibody, Sigma, St.
Louis, MO, USA). The blots were incubated with sec-
ondary antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), developed in chemiluminescence solu-
tion (Thermo Scientific, Rockford, IL USA). Quantifica-
tion of Western blots was done from the obtained
chemiluminescence values (BioRad, Hercules, CA, USA).
Target protein bands were normalized using the amount
of b-actin.
Immunohistochemistry
Immunohistochemical expression of GFAP, Iba1, TNFa
and NeuN in the spinal cord in rats with gp120 treatment
was investigated as described previously [62]. For immu-
nofluorescence detection, cryosections were probed over-
night with rabbit anti-GFAP polyclonal antibody (1 :
2000, DakoCytomation, Glostrup, Denmark), rabbit anti-
Iba1 antibody (1:1000, Wako, Richmond, VA), goat anti-
rat TNFa antibody (1 : 100; R&D systems, Minneapolis,
MN), mouse anti-NeuN monoclonal antibody (A60) (1 :
5000, Millipore, Billerica, MA), and then followed by
incubation with complementary secondary antibodies
labeled with blue-fluorescent Alexa Fluor 350, green-
fluorescent Alexa Fluor 488, or red-fluorescent Alexa
Fluor 594 (1 : 2000, Molecular Probes, Eugene, OR), 2 h
at room temperature and photographed using a fluores-
cence microscope. Sections were selected and scanned
using a Nikon fluorescence microscope.
Evaluation of the effect of TNFa siRNA in vitro
Glial cell line was used to verify the efficiency of TNFa
siRNA in vitro. TNFa siRNAs (forward 5’-GCCCGU
AGCCCACGUCGUAdTdT-3’, reverse-5’-UACGAC-
GUGGGCUACGGGCdTdT-3’) and mismatch siRNA
(forward-5’-GCCCGUAGAACACGUCGUAdTdT-3’,
reverse-5’-UACGACGUGUUCUACGGGCdTdT-3’) were
synthesized by Invitrogen (Invitrogen, CA, USA). We
demonstrated that cultured HAPI cells (a glial cell line)
treated with LPS, released TNFa [30]. In this study, HAPI
cells were seeded into 6-well plates at 2 × 105 cells/well 24
h before transfection. Transient transfection procedures
were performed according to Lipofectamine RNAiMAX
reagent instructions (Invitrogen, Camarillo, CA, USA).
Briefly, HAPI cells were incubated with 100 pmol siRNA
and 6 μl Lipofectamine RNAiMAX complexes in Opti-
MEM I reduced serum medium (Invitrogen, Camarillo,
CA, USA). Twenty four hours after siRNA application,
cells were stimulated by 1 ug/ml of LPS (Sigma, St. Louis,
MO, USA). Six hours after LPS, the supernatant was har-
vested and the concentration of TNFa was measured
using an ELISA kit (R&D Systems, Minneapolis, MN,
USA) according to the manufacturer’s instructions.
Drugs and Data Analysis
Recombinant gp120 was purchased from Immunodiag-
nostics (Woburn, MA) and dissolved in 0.1% RSA. Solu-
ble TNF receptor I was purchased from PeproTech and
dissolved in 0.1% RSA. Pentoxifylline was purchased
from Sigma (Sigma, St. Louis, MO) and dissolved in sal-
ine. The drug doses were selected on the basis of pre-
vious reports and our preliminary studies. To facilitate
siRNA into cells, we used polyethyleneimine (PEI), a
cationic polymer, as a delivery vehicle to prevent degra-
dation and enhance cell membrane penetration of
siRNA [63]. siRNA was dissolved in RNase-free water at
the concentration of 1 μg/μl as a stock solution. Ten
min before injection, 10 μl siRNA was mixed with 1.8 μl
PEI. Intrathecal drugs were injected through the
implanted polyethylene tubing (PE-10) within 10 μl fol-
lowed by 10 μl of saline; the injection lasted 30 s by
means of a Hamilton syringe.
The statistical significance of the differences was
determined by the t test. The difference between the
time-course curves of the behavioral testing was deter-
mined using a General Linear Model, repeated measure
with SPSS. P-values of less than 0.05 were considered to
be statistically significant.
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